Call for proposals to support the development of innovative medical countermeasures for chemical, biological, radiological and nuclear threats (HERA) – Medicinal products

Opened

Programme Category

EU Competitive Programmes

Programme Name

EU4Health Programme 2021-2027

Programme Description

The Programme aims to improve and promote health in the Union to reduce the burden of communicable and non-communicable diseases by:

  • protecting people from serious cross-border health threats
  • improving the availability, accessibility and affordability of medicines, medical devices and other crisis-related products in the EU
  • strengthening national health systems
Programme Details

Identifier Code

EU4H-2025-HERA-PJ-1-a

Call

Call for proposals to support the development of innovative medical countermeasures for chemical, biological, radiological and nuclear threats (HERA) – Medicinal products

Summary

The objective is to improve the Union’s readiness to respond to intentional health threats, including cross-border ones, by supporting the development of medical countermeasures to biological, chemical and radio-nuclear agents for which there currently are no or only limited treatment options.

This action will focus on supporting advanced research on threat-agnostic medical countermeasures against CBRN agents and platform approaches to treat injuries from CBRN agents.

Detailed Call Description

This action is expected to increase the preparedness of the Union to respond to CBRN threats and improve the availability of medical countermeasures against these threats. It should advance one or more medical countermeasures against CBRN threats along the steps towards regulatory approval and market readiness. In particular:

  • For countermeasures against biological threats, this includes vaccines, therapeutics (such as antivirals, small molecules, antimicrobials, monoclonals and polyclonals).
  • For countermeasures against chemical agents, this includes antidotes, supportive treatments, and innovation in application devices or techniques.
  • For countermeasures against radio-nuclear agents, treatments against acute radiation syndrome, against bone marrow suppression, and decorporation agents after exposure to radioactive substances.

Call Total Budget

€18.000.000

Financing percentage by EU or other bodies / Level of Subsidy or Loan

The costs will be reimbursed at the funding rate fixed in the Grant Agreement (60%).
You can apply for a higher project funding rate (80%) if your project is of ‘exceptional utility’, i.e. concerns:

  • actions where at least 30 % of the budget is allocated to Member States (or EU4H associated countries) whose GNI per inhabitant is less than 90% of the EU average or
  • actions with bodies from at least 14 Member States (or EU4H associated countries) and where at least four are from Member States (or EU4H associated countries) whose GNI per inhabitant is less than 90% of the EU average.

Grants may NOT produce a profit (i.e. surplus of revenues + EU grant over costs).
For-profit organisations must declare their revenues and, if there is a profit, we will deduct it from the final grant amount.

Thematic Categories

  • Health
  • Research, Technological Development and Innovation

Eligibility for Participation

  • Associations
  • Businesses
  • Educational Institutions
  • Large Enterprises
  • Legal Entities
  • NGOs
  • Other Beneficiaries
  • Private Bodies
  • Researchers/Research Centers/Institutions
  • Small and Medium Enterprises (SMEs)
  • State-owned Enterprises

Eligibility For Participation Notes

In order to be eligible, the applicants (beneficiaries and affiliated entities) must:

  • be legal entities (public or private bodies)
  • be established in one of the eligible countries, i.e.:
    • EU Member States (including overseas countries and territories (OCTs))
    • eligible non-EU countries:
      • listed EEA countries and countries associated to the EU4Health

Programme (list of participating countries)
Beneficiaries and affiliated entities must register in the Participant Register — before submitting the proposal — and will have to be validated by the Central Validation Service (REA Validation). For the validation, they will be requested to upload documents showing legal status and origin.

Other entities may participate in other consortium roles, such as associated partners, subcontractors, third parties giving in-kind contributions, etc

Consortium composition: Proposals can be submitted either by a single applicant or a consortium (no minimum requirement).

Eligible activities: Applications will only be considered eligible if their content corresponds wholly (or at least in part) to the topic description for which they are submitted.

Call Opening Date

04/09/2025

Call Closing Date

04/12/2025

National Contact Point(s)

Ministry of Health, Department of European Affairs

Ms MAKRIGIORGI Elena
Email: emakrigiorgi@moh.gov.cy

EU Contact Point

For help related to this call, please contact: HADEA-HP-CALLS@ec.europa.eu